Goto

Collaborating Authors

Results


KDD: Graph neural networks, fairness, and inclusivity

#artificialintelligence

As general chair of this year's ACM Conference on Knowledge Discovery and Data Mining (KDD), Huzefa Rangwala, a senior manager at the Amazon Machine Learning Solutions Lab, has a broad view of the topics under discussion there. Two of the most prominent, he says, are graph neural networks and fairness in AI. Graphs are data representations that can encode relationships between different data items, and graph neural networks are machine learning models that are useful for knowledge discovery because they can be used to infer graph structures. "Our world is connected in lots of ways, so you'll see graph neural networks find applications in lots of different domains, all the way from social networks and transportation networks to knowledge graphs and drug discovery," Rangwala says. The Amazon Machine Learning Solutions Lab brings the expertise of Amazon scientists and the resources of Amazon Web Services to bear on customers' machine learning problems.


Andrew Watson, Vice President of AI and R & D at Healx – Interview Series

#artificialintelligence

Andrew Watson is Vice President of AI and R & D at Healx. Prior to joining Healx he worked at the technology giant Dyson, where he was the founding member of the Machine Learning Research Department, leading the research and implementation of machine learning and artificial intelligence across a variety of global product categories. In his time as Director of Machine Learning at Dyson, Andrew also established a new research group, focused on the intersection between machine learning and cutting-edge biomedical research. Healx is an AI-powered, patient-inspired technology company, dedicated to helping rare disease patients around the world access life-improving therapies. There are 7,000 known rare diseases that affect 400 million people across the globe but only 5% of those conditions have approved treatments.


U-M receives NSF grant for data-driven drug discovery

#artificialintelligence

The Center for Data-Driven Drug Development and Treatment Assessment — to be known as DATA — will support the use of machine learning and …


Global Artificial Intelligence in Drug Discovery Market (2022 to 2027) – Benzinga

#artificialintelligence

Dublin, Aug. 12, 2022 (GLOBE NEWSWIRE) — The "Global Artificial Intelligence (AI) in Drug Discovery Market (2022-2027) by Offering, Drug Type, …


Aramco's Prosperity7 powers AI drug firm Insilico's $95M round – TechCrunch

#artificialintelligence

Hong Kong-based drug discovery and development company Insilico has secured fresh capital at a time that its CEO described as a "biotech winter." The firm has raised $35 million on the heels of its last tranche in June, bringing its total Series D investment to $95 million. The new round was "oversubscribed", the firm's founder and CEO Alex Zhavoronkov told TechCrunch, declining to disclose the company's valuation. Prosperity7, the venture capital arm of Saudi Arabia's state oil company Aramco, led the new capital infusion. The fund has been actively scouring for opportunities in and around China that can scale globally and particularly in the Middle East.


The Worldwide Artificial Intelligence (AI) in Drug Discovery Industry is Expected to … – The Facts

#artificialintelligence

Market dynamics are forces that impact the prices and behaviors of the Global Artificial Intelligence (AI) in Drug Discovery Market stakeholders.


A sequence-based global map of regulatory activity for deciphering human genetics - Nature Genetics

#artificialintelligence

Epigenomic profiling has enabled large-scale identification of regulatory elements, yet we still lack a systematic mapping from any sequence or variant to regulatory activities. We address this challenge with Sei, a framework for integrating human genetics data with sequence information to discover the regulatory basis of traits and diseases. Sei learns a vocabulary of regulatory activities, called sequence classes, using a deep learning model that predicts 21,907 chromatin profiles across >1,300 cell lines and tissues. Sequence classes provide a global classification and quantification of sequence and variant effects based on diverse regulatory activities, such as cell type-specific enhancer functions. These predictions are supported by tissue-specific expression, expression quantitative trait loci and evolutionary constraint data. Furthermore, sequence classes enable characterization of the tissue-specific, regulatory architecture of complex traits and generate mechanistic hypotheses for individual regulatory pathogenic mutations. We provide Sei as a resource to elucidate the regulatory basis of human health and disease. Sei is a new framework for integrating human genetics data with a sequence-based mapping of predicted regulatory activities to elucidate mechanisms contributing to complex traits and diseases.


Chemistry and digital chemistry: healthcare needs both

#artificialintelligence

At first glance, it almost sounds like an oxymoron. Surely there is nothing more analogue than how the building blocks of our world interact? Chemistry is all about lab work and real world experiments, no? All true, but digital chemistry – using computational techniques to solve complex chemical challenges – is a rapidly growing space (8,394 job postings worldwide on LinkedIn as I type). As we make advances in computer algorithms, artificial intelligence and machine learning, digital chemistry is becoming a vital tool for companies involved in any industry that relies upon solving chemical problems, from packaging to paint.


Aramco Backed Prosperity7 Ventures Leads Insilico Medicine $95M Series D

#artificialintelligence

Today Insilico Medicine announced the completion of a second closing of its Series D round, led by Prosperity7 Ventures, the diversified growth fund of Saudi Aramco Ventures, bringing the total Series D financing to $95 million. Other global investors with expertise in the biopharmaceutical and life sciences sectors also participated. The financing brought in Prosperity7 as a new investor, alongside current investors in the Series D round, including a large, diversified asset management firm on the US West Coast, B Capital Group, Warburg Pincus, BHR Partners, Qiming Venture Partners, Deerfield, Pavilion Capital, BOLD Capital Partners, and WS Investment Company. Insilico's founder and CEO, Alex Zhavoronkov, PhD, also invested in the Series D round. Insilico Medicine plans to grow its presence in Saudi Arabia, building on the recent investment from Prosperity7.


Inventing the Future: Artificial Intelligence (AI): A Tool for a Better Future

#artificialintelligence

"The development of full artificial intelligence could spell the end of the human race…it would take off on its own, and re-design itself at an ever-increasing rate. Humans, who are limited by slow biological evolution, couldn't compete, and would be superseded." Artificial Intelligence is undoubtedly one of the key technologies that defines the 21st century. Before throwing this two-word phrase around, having a general understanding of what Artificial Intelligence (AI) entails is important. To put it simply, AI is an attempt to emulate and simulate varied forms of human intelligence in machines.